[
    [
        {
            "time": "",
            "original_text": "【银河医药孟令伟/刘晖】公司点评丨万泰生物 (603392)：IVD+疫苗双轮驱动，业绩高速增长",
            "features": {
                "keywords": [
                    "万泰生物",
                    "IVD",
                    "疫苗",
                    "双轮驱动",
                    "业绩高速增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]